The Billion Dollar Blindspot
Subscribe
Sign in
Home
Capital Briefing
Archive
About
Why I Am Investing in Women’s Health Now
How demographics, science and technology, and cultural change are shaping the women’s health investment opportunity and where I see the strongest…
Oct 4
•
Maryann Selfe
21
4
5
Start Here
View all
Why I Am Investing in Women’s Health Now
How demographics, science and technology, and cultural change are shaping the women’s health investment opportunity and where I see the strongest…
Oct 4
•
Maryann Selfe
21
4
5
How Do You Actually Invest in Women’s Health?
Building an institutional portfolio approach to investing in women’s health
Sep 20
•
Maryann Selfe
18
3
5
Why Women's Health Is the First Test of Precision Health
How biological time is reshaping medicine, innovation and healthcare investing.
Jun 28
•
Maryann Selfe
14
6
The Billion Dollar Blindspot
Institutional investment intelligence on women’s health, Healthcare AI and the capital shaping the future of healthcare.
Subscribe
Recent posts
View all
The Precision Premium: A New Lens on Women’s Health Investing
What a sleeping pill revealed about female biology and why better understanding can lead to better healthcare and durable businesses.
2 hrs ago
•
Maryann Selfe
7
2
How Do You Actually Invest in Women’s Health?
Building an institutional portfolio approach to investing in women’s health
Sep 20
•
Maryann Selfe
18
3
5
Why Great Healthcare Ideas Still Fail
Some healthcare companies fail because the technology doesn’t work.
Aug 30
•
Maryann Selfe
12
1
4
26:15
What New Estrogen Research Tells Us About the Ageing Female Brain
The Daily Capital Briefing — 18 August 2026
Aug 18
•
Maryann Selfe
13
5
Menopause Competition Heats Up as Biotech’s Exit Market Strengthens
The Daily Capital Briefing — 12 August 2026
Aug 12
•
Maryann Selfe
6
2
2
Understand the science. Follow the capital.
Subscribe
News
View all
What New Estrogen Research Tells Us About the Ageing Female Brain
The Daily Capital Briefing — 18 August 2026
Aug 18
•
Maryann Selfe
13
5
Menopause Competition Heats Up as Biotech’s Exit Market Strengthens
The Daily Capital Briefing — 12 August 2026
Aug 12
•
Maryann Selfe
6
2
2
Women’s Health Hits a Record as Healthcare Capital Gets More Selective
The Daily Capital Briefing — 11 August 2026
Aug 11
•
Maryann Selfe
12
Ovarian Cancer Science Advances as Biotech’s Capital Machinery Starts to Reconnect
The Daily Capital Briefing — 10 August 2026
Aug 10
•
Maryann Selfe
9
1
Signal Not Noise
View all
UCB Just Paid $2.2 Billion for an Autoimmune Platform. The Indication List Tells You More Than the Deal Price.
UCB’s acquisition of Candid Therapeutics is being framed as a next-generation immunology platform deal. But beneath the immune-reset narrative lies a…
May 12
•
Maryann Selfe
17
4
4
Two Approved Drugs. The Same Structural Problem. What the Menopause Market Is Actually Telling Investors.
The first non-hormonal menopause drug launched in 2023. Two and a half years later, the commercial case has not arrived. Bayer launched its competitor…
May 5
•
Maryann Selfe
9
1
3
Sun Pharma Agreed to Pay $11.75 Billion for Organon. The Portfolio Is Women's Health. The Thesis Is Not.
The largest overseas acquisition in Indian pharmaceutical history transferred the world's biggest dedicated women's health portfolio to a biosimilar…
Apr 30
•
Maryann Selfe
3
4
2
Gilead Just Paid $5 Billion for a European Biotech. The Indication Was Ovarian Cancer. That's Not a Coincidence.
The largest private European biotech exit in history followed a pattern that was visible before the announcement. Here's how to read it and what it…
Apr 8
•
Maryann Selfe
3
1
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts
